Abstract 925P
Background
Response to immunotherapy in recurrent or metastatic head and neck squamous cell carcinoma (RM-HNSCC) varies among patients and depends on lesion features. This study evaluates the CD8 validated radiomics signature (RS) on the metastasis of RM-HNSCC patients to predict patient outcomes to nivolumab.
Methods
This study involved patients from the multi-institutional TOPNIVO phase II study (NCT03226756). At least 5 lesions per organ from each patient were delineated from baseline contrast enhanced CT scans. Features were extracted with the LIFEX software (IMIV/CEA, Orsay, France) and the RS was applied. Pre-treatment biopsies were used to quantify CD8 T-cells concentration (CD8C). The prognostic value of the CD8C and the minimum RS (mRS) were assessed, with values below the median classified as cold tumors.
Results
From 330 patients, 275 were eligible for the radiomics project, totaling 1371 lesions. CD8C was quantified from 133 patients providing a pre-treatment biopsy. CD8C was associated with PFS (HR=0.69, [0.49-0.69], P-value=0.042) and OS (HR=0.58, [0.40-0.84], P-value=0.004). The mRS was associated with OS (HR=0.70, [0.54-0.90], P-value=0.006). CD8C and mRS were independently associated with OS (HR=0.60, [0.41-0.88], P-value=0.009; HR=0.52, [0.34-0.77], P-value=0.001, multivariate analysis Table). Table: 925P
| Overall survival (HR [95%CI]) | P-value | Progression free survival (HR [95%CI]) | P-value | |
Age: ≥ 60 (vs ConclusionsThe least infiltrated lesion indicated by the mRS from metastatic lesions provide prognostic value in RM-HNSCC patients. This score could offer a valuable tool for clinicians to individualize management of RM-HNSCC under nivolumab. Clinical trial identificationNCT03226756. Editorial acknowledgementLegal entity responsible for the studyInstitut Gustave Roussy. FundingFondation ARC. DisclosureC. Even: Financial Interests, Personal, Advisory Board: BMS, MSD, Innate Pharma, Merck Serono; Financial Interests, Institutional, Advisory Board: F Star Therapeutics, Novartis, Elevar, BICARA, PDS Biotechnology, GSK, Merus; Financial Interests, Institutional, Local PI: BMS, AstraZeneca, ISA pharmaceutics, MSD, Debiopharma, Ayala, Gilead, GSK, Beigene, Takeda, Genmab, Seagen, Nykode; Financial Interests, Institutional, Coordinating PI: BMS, Novartis, sanofi. Y. Tao: Financial Interests, Institutional, Advisory Board: MSD, Bristol Myers Squibb; Financial Interests, Personal and Institutional, Funding: Onxeo, Merck; Financial Interests, Personal and Institutional, Advisory Board: Seagen. G. Lefebvre: Financial Interests, Personal and Institutional, Advisory Board: Bristol Myers Squibb; Financial Interests, Personal, Advisory Role: Merck. A. Daste: Financial Interests, Personal and Institutional, Expert Testimony: Merck; Financial Interests, Personal and Institutional, Advisory Board: Bristol Myers Squibb, Amgen; Financial Interests, Personal and Institutional, Funding: Merck. E.B. Saada: Financial Interests, Personal, Advisory Board: Merck Serono; Financial Interests, Personal, Invited Speaker: Merck Serono, MSD; Financial Interests, Coordinating PI: Novartis; Financial Interests, Institutional, Coordinating PI: Roche. J. Fayette: Financial Interests, Personal, Advisory Board: AstraZeneca, MSD, Innate Pharma, Merck, Serono, Roche, Pfizer, Hookipa; Non-Financial Interests, Principal Investigator: AstraZeneca, MSD, Pfizer, Meru, Calliditas, Isa. P. Blanchard: Financial Interests, Institutional, Invited Speaker: Ipsen, Sanofi Aventis, Janssen, MSD; Financial Interests, Personal, Invited Speaker, advisory board and speaker at conferences: Bayer; Financial Interests, Institutional, Advisory Board: Becton Dickinson; Financial Interests, Institutional, Full or part-time Employment, Editor in Chief - Clinical and Translational Radiation Oncology: ESTRO. M. Classe: Financial Interests, Personal and Institutional, Member: Sanofi. A. Auperin: Financial Interests, Personal, Advisory Board: MSD. E. Deutsch: Financial Interests, Personal, Advisory Board: Roche, Bristol Myers Squibb; Financial Interests, Personal, Funding: MSD, AstraZeneca, Boehringer Ingelheim Pharma GmbH & Co.KG; Financial Interests, Personal and Institutional, Advisory Board: Merck. All other authors have declared no conflicts of interest. Resources from the same session1025P - Fully intravenous delivery regimen of oncolytic adenovirus coding for TNFa and IL-2 (TILT-123) in patients with advanced solid cancersPresenter: Santeri Pakola Session: Poster session 03 1026P - Updated results from the phase I 1456-0001 study for intratumoral (IT) VSV-GP (BI 1831169) in patients with advanced solid tumorsPresenter: Stephane Champiat Session: Poster session 03 1027P - First results for intravenous (IV) VSV-GP (BI 1831169) in patients (pts) with advanced solid tumors from the 1456-0001 studyPresenter: Marc Oliva Bernal Session: Poster session 03 1028P - A phase I study of personalized KSX01-TCRT therapy for advanced solid tumor and its mechanismsPresenter: Shuhang Wang Session: Poster session 03 Resources: Abstract 1029P - Preclinical development of TCR-modified T cell therapies against mutated KRASPresenter: Hugh Salter Session: Poster session 03 1030P - Survival rates in high-risk neuroblastoma patients undergoing anti-GD2 immunotherapy: A single arm meta-analysis and systemic reviewPresenter: Lorena Escalante Romero Session: Poster session 03 1032P - Tumor-infiltrating lymphocytes with inducible membrane-tethered IL-12 cultured in optimized media exhibits superior anti-tumor activityPresenter: Patrick Innamarato Session: Poster session 03 1033P - Anti-tumor efficacy and safety of conditionally activated armored CAR-T cells against gastrointestinal tumorsPresenter: Zhihong Huang Session: Poster session 03 1034P - Preclinical development of genetically modified tumor-infiltrating lymphocytes using biopsy samples from liver cancer patientsPresenter: Mingyu Liu Session: Poster session 03 1035P - A new IL-6 inducing mechanism in cancer with new therapeutic possibilitiesPresenter: Leif Håkansson Session: Poster session 03 This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
|